Moncef Slaoui, GlaxoSmithKline

Moncef Slaoui, GlaxoSmithKline ($GSK)
2012 pay package: $4.61 million
2011 pay package: $4.89 million
Change: -5.72%
2012 Compensation: $1.15 million in salary; $1.40 million in bonus; $1.69 million in performance shares; $363,000 in other benefits

Dr. Moncef Slaoui took over as chairman of R&D in 2006, but his biggest task didn't begin until after CEO Andrew Witty stepped up in 2008. Since then, Slaoui has thrown out the company's R&D procedures and reorganized the research division into 38 smaller--and theoretically more nimble--individual units.

Last year wasn't a banner year, certainly, with a few new-drug approvals and a handful of new indications for existing meds. But that picture changed dramatically in 2013. The pharma giant has been racking up a record slate of regulatory approvals, which will likely jump to 5 soon with an OK for Anoro Ellipta, its new LAMA/LABA combo.

MenHibrix combination vaccine for infants, made up of two already-approved components, got the agency's backing in June. An anthrax antitoxin won the nod in mid-December, with a four-strain seasonal flu shot, FluLaval Quadrivalent, following on its heels. None of these products is considered blockbuster material, at least not yet. Meanwhile, the kidney cancer drug Votrient cleared the FDA to treat soft-tissue sarcoma. Perhaps most promising: Promacta got a new nod for hepatitis C patients, to stave off low platelet counts during interferon therapy. Its HIV drug Tivicay, from the ViiV Healthcare joint venture with Pfizer ($PFE), got the nod in August of this year, and it's expected to break the blockbuster barrier.

Still, there's a certain air of dissatisfaction about the progress the company has made. Its new drugs tend to fall short of creating a new standard of care. Added to that, its cancer vaccine MAGE-A3 just failed a key goal in a late-stage study, raising fears about its future and shifting the spotlight on blockbuster contenders to the heart drug darapladib.  

The company also advanced candidates further up the pipeline, with Phase III data due on 9 new drugs and vaccines in 2013 and 2014. One of them, the ground-gaining muscular dystrophy drug drisapersen, partnered with Prosensa ($RNA), landed the FDA's "breakthrough therapy" designation in June. Just days ago the FDA delivered breakthrough boasting rights for GSK's leukemia drug Arzerra as a first-line therapy.

For more:

Special Report: GlaxoSmithKline - Biopharma's Top R&D Spenders - 2012
GlaxoSmithKline stakes a pioneering effort to launch 'electroceutical' R&D
GSK's Slaoui talks up 'innovative' late-stage pipeline as regulatory reviews loom
GlaxoSmithKLine gains FDA OK on two genetically targeted melanoma drugs

-- Skye Toor

Moncef Slaoui, GlaxoSmithKline

Suggested Articles

Plexium is launching with $28 million to build its platform and a pipeline of drugs that target the enzymes drive recognition of protein targets.

In this week's EuroBiotech Report, Healx raises $56 million, Boehringer's VC wing backs anti-cancer virus startup and Ipsen bags Blueprint drug.

In our EuroBiotech roundup this week, GammaDelta forms antibody spinout, gene therapy startup raises cash and Amsterdam plans medical business park.